Evidence map›Paper›PMID 37770004›Full record

ReviewEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2023

On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI).

Jodi Graf, Michael Trautmann-Rodriguez, Simone Sabnis, April M Kloxin, Catherine A Fromen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jodi GrafDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Michael Trautmann-RodriguezDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Simone SabnisDepartment of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.
April M KloxinDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA; Department of Materials Science and Engineering, University of Delaware, Newark, DE 19716, USA. Electronic address: akloxin@udel.edu.
Catherine A FromenDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA. Electronic address: cfromen@udel.edu.
University of Delaware · US

Funding

Multiscale considerations for immune engineering at mucosal interfacesR35GM142866 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine A Fromen · 2021 to 2026
$2.4M
Unraveling fibrosis with dynamic microenvironments and molecular toolsDP2HL152424 · NHLBI · UNIVERSITY OF DELAWARE · PI KLOXIN, APRIL M · 2019 to 2019
$2.4M
NHLBI NIH HHS DP2 HL152424NIGMS NIH HHS R35 GM142866
6 · The paper itself

Abstract

Chronic respiratory diseases and infections are among the largest contributors to death globally, many of which still have no cure, including chronic obstructive pulmonary disorder, idiopathic pulmonary fibrosis, and respiratory syncytial virus among others. Pulmonary therapeutics afford untapped potential for treating lung infection and disease through direct delivery to the site of action. However, the ability to innovate new therapeutic paradigms for respiratory diseases will rely on modeling the human lung microenvironment and including key cellular interactions that drive disease. One key feature of the lung microenvironment is the air-liquid interface (ALI). ALI interface modeling techniques, using cell-culture inserts, organoids, microfluidics, and precision lung slices (PCLS), are rapidly developing; however, one major component of these models is lacking-innate immune cell populations. Macrophages, neutrophils, and dendritic cells, among others, represent key lung cell populations, acting as the first responders during lung infection or injury. Innate immune cells respond to and modulate stromal cells and bridge the gap between the innate and adaptive immune system, controlling the bodies response to foreign pathogens and debris. In this article, we review the current state of ALI culture systems with a focus on innate immune cells and suggest ways to build on current models to add complexity and relevant immune cell populations.

Indexed as

Pulmonary Disease, Chronic ObstructiveRespiratory Syncytial Virus, HumanHumansImmunityImmunity, InnateLungMacrophagesAir-liquid interfaceMucosal immunityPulmonary therapeuticsRespiratory disease modeling

Identifiers

PMID37770004
PMCPMC10658361
OpenAlexW4387035658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.